Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.

Abstract

BACKGROUND:

With the aim of evaluating the results of multidisciplinary approaches, we reviewed our experience in multimodality treatment of advanced stage (III and IVA) thymic tumors.

METHODS:

From 1976 to 2003, 56 patients with Masaoka stage III and IVA thymic tumors underwent a multimodality treatment. Thirty-six patients underwent neoadjuvant chemotherapy, surgery, and postoperative radiotherapy; 20 patients were treated by primary surgery and postoperative radiotherapy (n = 12), chemotherapy (n = 1) or chemoradiotherapy (n = 7). The neoadjuvant or adjuvant chemotherapy consisted of three courses of cisplatin, epidoxorubicin, and etoposide every 3 weeks. Adjuvant radiotherapy consisted of 45 Gy for complete resections or 60 Gy for incomplete resections.

RESULTS:

The preoperative diagnosis of invasive thymomas was performed in a total of 29 cases: 15 by mediastinotomy, 6 by video-assisted thoracoscopic surgery, and 8 by fine-needle aspiration. In 27 cases no diagnosis was available, but in most of them a thymus-related syndrome was present. Thirty-four patients are still alive (31 disease-free), and 22 have died (2 disease-free). Ten-year survival was 48% and 45.7% for stage III and IVA thymomas, respectively. The presence of myasthenia gravis (p = 0.04) and neoadjuvant chemotherapy (p = 0.004) affected survival significantly.

CONCLUSIONS:

The multimodality treatment of stage III and IVA thymic tumors allows a good long-term outcome; the neoadjuvant chemotherapy improves the resectability rate and the survival of both stages of the disease.

• Authors: Marco Lucchi, Marcello Carlo Ambrogi, Leonardo Duranti, Fulvio Basolo, Gabriella Fontanini, Carlo Alberto Angeletti, Alfredo Mussi
• Journal: The Annals of thoracic surgery (Ann Thorac Surg) Vol. 79 Issue 6 Pg. 1840-4 (Jun 2005) ISSN: 1552-6259 [Electronic] Netherlands
• PMID: 15919267 (Publication Type: Journal Article)

Chemical References

• Epirubicin
• Etoposide
• Cisplatin

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma (drug therapy, pathology, radiotherapy, surgery)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Epirubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Humans
• Male
• Middle Aged
• Myasthenia Gravis (complications)
• Neoadjuvant Therapy
• Radiotherapy, Adjuvant
• Retrospective Studies
• Survival Analysis
• Thymoma (drug therapy, pathology, radiotherapy, surgery)
• Thymus Neoplasms (drug therapy, pathology, radiotherapy, surgery)
• Treatment Outcome